Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | CCNK | O75909 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485796 | 1.00 | AKT1 (0.34) | AKT1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL20485938 | 0.97 | AKT1 (0.36) | AKT1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL20485972 | 0.95 | AKT1 (0.35) | AKT1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL17454964 | 0.83 | ALDH1A1 (0.30) | ALDH1A1PDE2A | |
| SCHEMBL15464699 | 0.81 | ALDH1A1 (0.32) | MEN1KMT2ASMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL15465123 | 0.81 | ALDH1A1 (0.32) | MEN1KMT2ASMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL15465508 | 0.81 | ALDH1A1 (0.32) | MEN1KMT2ASMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL18192096 | 0.81 | ALDH1A1 (0.32) | MEN1KMT2ASMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL20485790 | 0.79 | SCN9A (0.38) | AKT1 | |
| SCHEMBL20486319 | 0.79 | SCN9A (0.38) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-06-11 | — | — | US | disclosed |
| EP-3372583-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-12 | — | — | EP | disclosed |
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251448-A1 | METHOD FOR REMOVING DIMETHOXYBENZYL GROUP | DDT, ALKBH5, DDO | AKT1 2012/4885MEN1 425/4885KMT2A 246/4885 |
| US-10316026-B2 | Method for removing dimethoxybenzyl group | DDT, ALKBH5, DDO | AKT1 2012/4885MEN1 425/4885KMT2A 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.